Clinical Trial Update: Study to Test the Safe and Effective Use of an e-Device for the Self-injection of Certolizumab Pegol Solution by Subjects With Moderate to Severe Active Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis, or Moderately to Severely Active Crohn's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating a self-injection e-device for certolizumab pegol in several inflammatory diseases; study completed with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Crohn Disease
• Psoriatic Arthritis
• Rheumatoid Arthritis

Drugs mentioned

• Certolizumab pegol (certolizumab pegol)

Snippet

Sponsor: UCB Biopharma S.P.R.L. | Conditions: Moderate and Severe Active Rheumatoid Arthritis, Active Psoriatic Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2019-10-25